Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_1
4
57%
Ph phase_3
1
14%

Phase Distribution

4

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (57.1%)
Phase 22 (28.6%)
Phase 31 (14.3%)

Trials by Status

terminated229%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449
terminatedphase_2

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

NCT03382899
completedphase_3

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

NCT02923921
terminatedphase_2

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

NCT03382912
completedphase_1

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

NCT04194892
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02009449Phase 1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Completed
NCT03382899Phase 2

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Terminated
NCT02923921Phase 3

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Completed
NCT03382912Phase 2

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Terminated
NCT04194892Phase 1

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

Completed
NCT03267732Phase 1

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Completed
NCT03381547Phase 1

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7